Molecular Partners AG, a clinical-stage biotech company, has announced a strategic partnership with Orano Med, a clinical-stage radiopharmaceutical company. This collaboration aims to develop a new class of targeted alpha-particle therapies using Molecular Partners' proprietary DARPin therapeutics platform. The joint effort has led to the nomination of MP0726, a Radio-DARPin candidate targeting mesothelin, for the treatment of ovarian cancer. Demonstrating promising preclinical results, this partnership combines Molecular Partners' expertise in custom-built protein drugs with Orano Med's advanced radiopharmaceutical capabilities, positioning them to address important unmet medical needs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。